FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

New Mailing Address for Therapeutic Biological Products Documents Important update for mailing THERAPEUTIC Biological Products submissions Beginning October 4, 2004, all therapeutic biologic submissions (EXCLUDING 21 CFR 600.80 postmarketing adverse experience reports; advertising and promotional labeling; and 21 CFR 600.14 biological product deviation reports) should be sent to: CDER Therapeutic Biological Products Document Room Center for Drug Evaluation and Research Food and Drug Administration 12229 Wilkins Avenue Rockville, MD 20852 On June 30, 2003, FDA transferred some of the therapeutic biological products that had been reviewed and regulated by the Center for Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and Research (CDER). CDER now has regulatory responsibility, including premarket review and continuing oversight, over the transferred products. In regulating the products assigned to them, CBER and CDER will consult with each other regularly and whenever necessary. On October 1, 2003, the staff comprising CBER’s Office of Therapeutics Research and Review also transferred to CDER. CDER created two new offices to accommodate the former CBER staff: the Office of Drug Evaluation VI, within CDER’s Office of New Drugs, and the Office of Biotechnology Products, within CDER’s Office of Pharmaceutical Science. For further information about the organizational structure of the two new offices in CDER, see www.fda.gov/cder/biologics/default.htm. The lists below identify categories of therapeutic biological products transferred from CBER to CDER, and categories of therapeutic biological products remaining in CBER. Please note that the CBER list contains only a portion of the products CBER currently regulates; this list contains products that are closely related in chemical structure to products that transferred to CDER, e.g. therapeutic proteins and polysaccharides. Products are included on the CBER list as a means of clarifying the products that transferred and those that did not. Product information for the product classes transferring to CDER have been relocated to the CDER web site. A list of specific products transferring to CDER is provided. Product information for the product classes remaining in CBER will remain on the CBER web site. Categories of Therapeutic Biological Products Transferred to CDER Monoclonal antibodies for in-vivo use Proteins intended for therapeutic use, including cytokines (e.g. interferons), enzymes (e.g. thrombolytics), and other novel proteins, except for those that are specifically assigned to CBER (e.g., vaccines and blood products). This category includes therapeutic proteins derived from plants, animals, or microorganisms, and recombinant versions of these products Immunomodulators (non-vaccine and non-allergenic products intended to treat disease by inhibiting or modifying a pre-existing immune response) Growth factors, cytokines, and monoclonal antibodies intended to mobilize, stimulate, decrease or otherwise alter the production of hematopoietic cells in vivo 1 Categories of Therapeutic Biological Products Remaining in CBER Cellular products, including products composed of human, bacterial or animal cells (such as pancreatic islet cells for transplantation), or from physical parts of those cells (such as whole cells, cell fragments, or other components intended for use as preventative or therapeutic vaccines) Vaccines (products intended to induce or increase an antigen specific immune response for prophylactic or therapeutic immunization, regardless of the composition or method of manufacture) Allergenic extracts used for the diagnosis and treatment of allergic diseases and allergen patch tests Antitoxins, antivenins, and venoms Blood, blood components, plasma derived products (for example, albumin, immunoglobulins, clotting factors, fibrin sealants, proteinase inhibitors), including recombinant and transgenic versions of plasma derivatives, (for example clotting factors), blood substitutes, plasma volume expanders, human or animal polyclonal antibody preparations including radiolabeled or conjugated forms, and certain fibrinolytics such as plasma-derived plasmin, and red cell reagents Combination Products The lists above contain some combination products comprised of a biological product component with a device and/or drug component, though such products are not specifically identified. Combination products are assigned to a Center for review and regulation in accordance with the products’ primary mode of action. 2 When a product’s primary mode of action is attributable to a type of biological product assigned to CDER, the product will be assigned to CDER. Similarly, when a product’s primary mode of action is attributable to a type of biological product assigned to CBER, the product will be assigned to CBER. For further information about combination products, see http://www.fda.gov/oc/combination, or contact the Office of Combination Products at 301-827-9229,or combination@fda.gov. Sponsor Information Files transfering to CDER BLA NDA IND IDE Files remaining with CBER BLA NDA IND IDE Letter to Sponsors - (PDF), (Text) FEDERAL REGISTER Drug and Biological Product Consolidation - 6/26/2003 - (PDF), (Text)   Questions about the assignment of specific products to CBER or CDER should be directed to the center jurisdiction officers at: CDER Ombudsman ......................... 301-594-5480 CBER Ombudsman ......................... 301-827-0379   Footnotes 1Growth factors, cytokines, and monoclonal antibodies intended to mobilize, stimulate, decrease or otherwise alter the production of hematopoietic cells in vivo, for the purpose of being harvested for use in the production of a therapeutic cellular or blood product, may be regulated in combination with the therapeutic cellular or blood product, as appropriate. Sponsors of products that fit this description should contact the center jurisdiction officers listed below for guidance on appropriate center assignment. 2 See 21 U.S.C. § 353(g), section 503(g) of the Federal Food, Drug, and Cosmetic Act.   Updated September 27, 2004   CBER Home Page | CBER A-Z Index | CBER Search | Contact CBER FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page FDA / Center for Biologics Evaluation and Research